Health Trials

Cilostazol for Prevention of Recurrent Stroke Trial

ConditionsStroke RecurrenceMyocardial InfarctionVascular DeathIschemic StrokeTIA (Transient Ischemic Attack)Stroke (CVA) or Transient Ischemic AttackRecurrent Stroke
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age40+
SponsorStanford University

About this trial

The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.

Eligibility criteria

Qualifiers

Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days

Currently taking aspirin or clopidogrel (not both) to prevent another stroke

Disqualifiers

Had a spontaneous brain bleed within the last 2 years.

Moderate to severe heart failure.

Life expectancy is less than 6 months.

Trial design

Treatments tested in this trial

  • Cilostazol 100 mg
  • Placebo

Treatment groups

2,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Stanford University

Lead sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Yale University

Collaborator

University of Cincinnati

Collaborator

Medical University of South Carolina

Collaborator

Source ClinicalTrials.gov